That which is claimed is:

1. Use of an effective amount of 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a subject with sarcoidosis.

2. The use of claim 1 wherein said subject has chronic sarcoidosis.

3. The use of claim 1 wherein said sarcoidosis affects the lungs, liver, heart, nervous system, skin, lymph glands, musculoskeletal system, spleen, eyes, sinuses, nasal mucosa, larynx, the gastrointestinal tract, reproductive organs, salivary glands and/or kidneys.

4. The use of claim 3 wherein said sarcoidosis affects the lungs.

5. The use of claim 1 wherein at least 1mg/kg of 1,3-propanedisulfonic acid or pharmaceutically acceptable salt thereof is to be administered to said subject per dose.

6. The use of claim 5 wherein said 1,3-propanedisulfonic acid or pharmaceutically acceptable salt thereof is to be administered more than once daily.

7. The use of claim 5 wherein said 1,3-propanedisulfonic acid or pharmaceutically acceptable salt thereof is to be administered 2, 3, 4, 5 or 6 times daily.

8. The use of claim 5 wherein no more than 20mg/kg of 1,3-propanedisulfonic acid or pharmaceutically acceptable salt thereof is to be administered to said subject per dose.

9. The use of claim 1 wherein said 1,3-propanedisulfonic acid or pharmaceutically acceptable salt thereof is to be administered by oral, parenteral, intraperitoneal, intraspinal, intracerebral, nasal, mucosal, transdermal, intravascular, intraarterial, intramuscular, or subcutaneous delivery.

10. The use of claim 1 wherein said 1,3-propanedisulfonic acid or pharmaceutically acceptable salt thereof is to be administered by oral delivery.

11. The use of any one of the preceding claims wherein said 1,3-propanedisulfonic acid or pharmaceutically acceptable salt thereof is 1,3-propanedisulfonic acid.

12. The use of any one of claims 1 – 10 wherein said 1,3-propanedisulfonic acid or pharmaceutically acceptable salt thereof is the disodium salt of 1,3-propanedisulfonic acid.